Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study Meeting Abstract
| Authors: | D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; Bernthal, N. M.; van de Sande, M.; Narasimhan, S.; Harrow, B.; Saunders, A.; Ruiz-Soto, R.; Sherman, M. L.; Tap, W. D. |
| Abstract Title: | Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1054 |
| Language: | English |
| ACCESSION: | WOS:001326612902390 |
| DOI: | 10.1016/j.annonc.2024.08.1861 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1770P -- Source: Wos |
